Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organometallic Compounds | 2 | 2019 | 209 | 0.860 |
Why?
|
| Cyclotrons | 1 | 2019 | 10 | 0.690 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 1095 | 0.480 |
Why?
|
| Gallium Radioisotopes | 2 | 2019 | 62 | 0.430 |
Why?
|
| Radioimmunotherapy | 2 | 2020 | 128 | 0.410 |
Why?
|
| Radium | 2 | 2021 | 97 | 0.340 |
Why?
|
| Radiopharmaceuticals | 5 | 2021 | 1341 | 0.320 |
Why?
|
| Luciferases | 2 | 2010 | 460 | 0.320 |
Why?
|
| T-Lymphocytes | 6 | 2011 | 3944 | 0.290 |
Why?
|
| Biotin | 1 | 2006 | 78 | 0.260 |
Why?
|
| Iodine Radioisotopes | 2 | 2018 | 387 | 0.220 |
Why?
|
| Antigens, CD19 | 4 | 2011 | 584 | 0.220 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 5867 | 0.210 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 661 | 0.190 |
Why?
|
| Gallium Isotopes | 1 | 2019 | 7 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2011 | 1840 | 0.170 |
Why?
|
| Kidney | 2 | 2020 | 2121 | 0.170 |
Why?
|
| Automation | 1 | 2019 | 154 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 134 | 0.160 |
Why?
|
| Cadherins | 1 | 2020 | 657 | 0.140 |
Why?
|
| Tissue Kallikreins | 1 | 2016 | 9 | 0.140 |
Why?
|
| Receptors, Fc | 1 | 2016 | 72 | 0.140 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 366 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2664 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2018 | 161 | 0.130 |
Why?
|
| Cell Line, Tumor | 9 | 2021 | 14841 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 247 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 1335 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 637 | 0.120 |
Why?
|
| Thyroid Neoplasms | 2 | 2018 | 1894 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2011 | 714 | 0.120 |
Why?
|
| Antibodies | 1 | 2016 | 809 | 0.110 |
Why?
|
| Mice | 15 | 2021 | 35598 | 0.110 |
Why?
|
| Carcinoma, Papillary | 2 | 2018 | 566 | 0.110 |
Why?
|
| Gene Expression | 1 | 2021 | 3642 | 0.100 |
Why?
|
| Diphenylamine | 2 | 2011 | 16 | 0.100 |
Why?
|
| Mice, SCID | 4 | 2011 | 1825 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 854 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 2455 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2014 | 314 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 68 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 1129 | 0.090 |
Why?
|
| Leukemia, B-Cell | 1 | 2011 | 114 | 0.090 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2010 | 23 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2021 | 4329 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4961 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3031 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2014 | 929 | 0.080 |
Why?
|
| Animals | 15 | 2021 | 62051 | 0.080 |
Why?
|
| Coleoptera | 1 | 2009 | 19 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 7915 | 0.080 |
Why?
|
| Positron-Emission Tomography | 4 | 2016 | 2196 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2011 | 350 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2399 | 0.080 |
Why?
|
| Indium Radioisotopes | 2 | 2020 | 63 | 0.080 |
Why?
|
| Graft Survival | 1 | 2011 | 1082 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4480 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 885 | 0.070 |
Why?
|
| Pyridones | 1 | 2010 | 360 | 0.070 |
Why?
|
| Fluorine Radioisotopes | 1 | 2007 | 139 | 0.070 |
Why?
|
| Streptavidin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Immunoglobulin Fragments | 1 | 2006 | 27 | 0.070 |
Why?
|
| Benzamides | 2 | 2011 | 1879 | 0.070 |
Why?
|
| Whole-Body Counting | 1 | 2006 | 25 | 0.070 |
Why?
|
| Indoles | 1 | 2011 | 1028 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2010 | 3669 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 313 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 242 | 0.060 |
Why?
|
| Adoptive Transfer | 2 | 2010 | 431 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2009 | 878 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2006 | 203 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 1838 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 655 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 1642 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2006 | 737 | 0.060 |
Why?
|
| Male | 10 | 2021 | 128463 | 0.060 |
Why?
|
| Thiazoles | 1 | 2007 | 723 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 1655 | 0.050 |
Why?
|
| Humans | 17 | 2021 | 270880 | 0.050 |
Why?
|
| B7-1 Antigen | 1 | 2003 | 84 | 0.050 |
Why?
|
| Lymphocyte Activation | 4 | 2011 | 1723 | 0.050 |
Why?
|
| Cell Movement | 1 | 2010 | 2472 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2009 | 3045 | 0.050 |
Why?
|
| Neoplasms | 3 | 2020 | 15933 | 0.050 |
Why?
|
| Isotope Labeling | 2 | 2014 | 149 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 1946 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2011 | 1933 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2003 | 190 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 7103 | 0.050 |
Why?
|
| Electroporation | 1 | 2021 | 127 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2010 | 7237 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 5171 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2020 | 231 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3346 | 0.040 |
Why?
|
| Vaccination | 1 | 2006 | 1164 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2020 | 286 | 0.040 |
Why?
|
| Thyroglobulin | 1 | 2018 | 65 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 2020 | 210 | 0.040 |
Why?
|
| Retroviridae | 2 | 2011 | 373 | 0.040 |
Why?
|
| NIH 3T3 Cells | 2 | 2011 | 255 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 255 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 726 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 1028 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 4018 | 0.040 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 131 | 0.040 |
Why?
|
| Testis | 1 | 2020 | 620 | 0.040 |
Why?
|
| Transduction, Genetic | 2 | 2011 | 494 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 1424 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 1064 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2011 | 3919 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 2014 | 49 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2014 | 73 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2007 | 2903 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2009 | 12103 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 3588 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 4048 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2011 | 30 | 0.030 |
Why?
|
| Female | 6 | 2020 | 149029 | 0.020 |
Why?
|
| Survival Rate | 2 | 2021 | 12538 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 3088 | 0.020 |
Why?
|
| Luminescence | 1 | 2010 | 45 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5595 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2010 | 384 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 96 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 562 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2010 | 404 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 158 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 164 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2010 | 320 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2010 | 329 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2011 | 366 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 345 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3300 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5149 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 14617 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2011 | 683 | 0.020 |
Why?
|
| Point Mutation | 1 | 2011 | 788 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4499 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 1811 | 0.020 |
Why?
|
| Dideoxynucleosides | 1 | 2007 | 17 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 5759 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 1428 | 0.020 |
Why?
|
| G1 Phase | 1 | 2007 | 305 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 563 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2007 | 305 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 2045 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5310 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 1193 | 0.020 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2005 | 16 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2453 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 195 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 1032 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 5404 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 484 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1054 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6516 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 14012 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2007 | 487 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2005 | 306 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 9042 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2005 | 228 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2011 | 3145 | 0.010 |
Why?
|
| Dasatinib | 1 | 2007 | 881 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2196 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4224 | 0.010 |
Why?
|
| DNA Damage | 1 | 2011 | 1988 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 15223 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 13420 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2005 | 380 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3244 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 3485 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3215 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4877 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10395 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 5339 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2007 | 1144 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 334 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 763 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 7784 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 22501 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 73417 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2005 | 1135 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9039 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 16670 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 2808 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 15911 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 90382 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7754 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 33756 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2003 | 2439 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2930 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 7386 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 7017 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 82036 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 10707 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 12027 | 0.000 |
Why?
|